Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Curetis

BATS-CHIXE:CUREA
Snowflake Description

Worrying balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CUREA
BATS-CHIXE
€15M
Market Cap
  1. Home
  2. GB
  3. Healthcare
Company description

Curetis N.V., a commercial-stage molecular diagnostics company, provides solutions for laboratories, pharma-companies, and public hospitals in Germany and internationally. The last earnings update was 134 days ago. More info.


Add to Portfolio Compare Print
  • Curetis has significant price volatility in the past 3 months.
CUREA Share Price and Events
7 Day Returns
-47.9%
BATS-CHIXE:CUREA
-1.2%
GB Medical Equipment
0.1%
GB Market
1 Year Returns
-53.6%
BATS-CHIXE:CUREA
-0.3%
GB Medical Equipment
-23.6%
GB Market
CUREA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Curetis (CUREA) -47.9% -18% -20.7% -53.6% - -
GB Medical Equipment -1.2% -12% -19.1% -0.3% -2.3% 20.9%
GB Market 0.1% -15.5% -27% -23.6% -24.3% -23.5%
1 Year Return vs Industry and Market
  • CUREA underperformed the Medical Equipment industry which returned -0.3% over the past year.
  • CUREA underperformed the Market in United Kingdom of Great Britain and Northern Ireland which returned -23.6% over the past year.
Price Volatility
CUREA
Industry
5yr Volatility vs Market

CUREA Value

 Is Curetis undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Curetis is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Curetis has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Curetis. This is due to cash flow or dividend data being unavailable. The share price is €0.557.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Curetis's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Curetis's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BATS-CHIXE:CUREA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in EUR €-1.02
ENXTAM:CURE Share Price ** ENXTAM (2020-04-03) in EUR €0.56
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry PE Ratio Median Figure of 11 Publicly-Listed Medical Equipment Companies 25.55x
United Kingdom of Great Britain and Northern Ireland Market PE Ratio Median Figure of 748 Publicly-Listed Companies 12.61x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Curetis.

BATS-CHIXE:CUREA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTAM:CURE Share Price ÷ EPS (both in EUR)

= 0.56 ÷ -1.02

-0.55x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Curetis is loss making, we can't compare its value to the GB Medical Equipment industry average.
  • Curetis is loss making, we can't compare the value of its earnings to the United Kingdom of Great Britain and Northern Ireland market.
Price based on expected Growth
Does Curetis's expected growth come at a high price?
Raw Data
BATS-CHIXE:CUREA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.55x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry PEG Ratio Median Figure of 8 Publicly-Listed Medical Equipment Companies 2x
United Kingdom of Great Britain and Northern Ireland Market PEG Ratio Median Figure of 517 Publicly-Listed Companies 0.99x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Curetis, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Curetis's assets?
Raw Data
BATS-CHIXE:CUREA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in EUR €-0.15
ENXTAM:CURE Share Price * ENXTAM (2020-04-03) in EUR €0.56
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry PB Ratio Median Figure of 20 Publicly-Listed Medical Equipment Companies 2.83x
United Kingdom of Great Britain and Northern Ireland Market PB Ratio Median Figure of 1,323 Publicly-Listed Companies 1.11x
BATS-CHIXE:CUREA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTAM:CURE Share Price ÷ Book Value per Share (both in EUR)

= 0.56 ÷ -0.15

-3.76x

* Primary Listing of Curetis.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Curetis has negative assets, we can't compare the value of its assets to the GB Medical Equipment industry average.
X
Value checks
We assess Curetis's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Curetis has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

CUREA Future Performance

 How is Curetis expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Curetis has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
21.1%
Expected Medical Equipment industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Curetis expected to grow at an attractive rate?
  • Unable to compare Curetis's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Curetis's earnings growth to the United Kingdom of Great Britain and Northern Ireland market average as no estimate data is available.
  • Unable to compare Curetis's revenue growth to the United Kingdom of Great Britain and Northern Ireland market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
BATS-CHIXE:CUREA Future Growth Rates Data Sources
Data Point Source Value (per year)
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 21.1%
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 6.2%
United Kingdom of Great Britain and Northern Ireland Market Earnings Growth Rate Market Cap Weighted Average 15.5%
United Kingdom of Great Britain and Northern Ireland Market Revenue Growth Rate Market Cap Weighted Average 2.5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BATS-CHIXE:CUREA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BATS-CHIXE:CUREA Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
BATS-CHIXE:CUREA Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2019-09-30 2 -17 -22
2019-06-30 2 -18 -23
2019-03-31 2 -21 -23
2018-12-31 1 -22 -24
2018-09-30 2 -22 -23
2018-06-30 1 -20 -21
2018-03-31 1 -17 -21
2017-12-31 1 -16 -19
2017-09-30 1 -18 -19
2017-06-30 1 -17 -18
2017-03-31 2 -16 -16
2016-12-31 1 -16 -15

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Curetis is high growth as no earnings estimate data is available.
  • Unable to determine if Curetis is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BATS-CHIXE:CUREA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Curetis Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BATS-CHIXE:CUREA Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
BATS-CHIXE:CUREA Past Financials Data
Date (Data in EUR Millions) EPS *
2019-09-30 -1.02
2019-06-30 -1.18
2019-03-31 -1.25
2018-12-31 -1.41
2018-09-30 -1.44
2018-06-30 -1.38
2018-03-31 -1.35
2017-12-31 -1.26
2017-09-30 -1.22
2017-06-30 -1.16
2017-03-31 -1.06
2016-12-31 -0.98

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Curetis will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Curetis's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Healthcare companies here
  2. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Curetis's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Curetis has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

CUREA Past Performance

  How has Curetis performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Curetis's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Curetis does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Curetis's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Curetis's 1-year growth to the GB Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
Curetis's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Curetis Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BATS-CHIXE:CUREA Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 1.61 -22.38 11.51 9.44
2019-06-30 1.70 -23.26 11.21 10.07
2019-03-31 1.64 -22.55 11.77 10.36
2018-12-31 1.42 -23.75 12.25 10.57
2018-09-30 1.55 -22.64 12.16 9.63
2018-06-30 1.40 -21.40 11.69 8.88
2018-03-31 1.33 -20.93 11.40 8.13
2017-12-31 1.19 -19.50 11.06 7.36
2017-09-30 1.06 -19.01 10.82 6.80
2017-06-30 1.25 -18.13 10.31 6.89
2017-03-31 1.52 -16.35 9.19 6.95
2016-12-31 1.31 -15.17 8.12 7.03
2016-09-30 2.28 -10.39 7.19 7.39
2016-06-30 2.00 19.51 6.12 7.07
2016-03-31 1.99 13.26 5.95 6.86
2015-12-31 2.09 13.84 5.39 6.71
2015-09-30 0.90 10.63 4.55 6.05
2015-06-30 0.76 -18.10 4.36 5.94
2015-03-31 0.38 -11.67 3.63 6.04
2014-12-31 0.27 -12.43 3.58 6.30
2013-12-31 0.67 -10.72 2.83 5.89

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Curetis has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Curetis has efficiently used its assets last year compared to the GB Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Curetis improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Curetis's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Curetis has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

CUREA Health

 How is Curetis's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Curetis's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Curetis is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Curetis's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Curetis's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Curetis has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Curetis Company Filings, last reported 6 months ago.

BATS-CHIXE:CUREA Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 -3.68 21.92 3.05
2019-06-30 0.02 22.99 7.81
2019-03-31 5.24 17.21 6.16
2018-12-31 9.05 17.06 10.28
2018-09-30 8.69 13.77 5.54
2018-06-30 14.68 13.60 11.65
2018-03-31 16.72 10.47 11.37
2017-12-31 22.20 10.34 16.31
2017-09-30 26.86 0.00 21.56
2017-06-30 31.64 0.00 25.40
2017-03-31 36.44 0.00 19.31
2016-12-31 40.36 0.00 22.83
2016-09-30 44.43 0.00 35.42
2016-06-30 48.10 0.00 39.71
2016-03-31 51.63 0.00 43.19
2015-12-31 54.79 0.00 46.06
2015-09-30
2015-06-30 -130.91 139.61 5.94
2015-03-31 -118.54 126.43 2.99
2014-12-31 -118.54 126.04 2.99
2013-12-31 -106.10 116.99 5.38
  • Curetis has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Curetis's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Curetis has less than a year of cash runway based on current free cash flow.
  • Curetis has less than a year of cash runway if free cash flow continues to grow at historical rates of 17.5% each year.
X
Financial health checks
We assess Curetis's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Curetis has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

CUREA Dividends

 What is Curetis's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Curetis dividends.
If you bought €2,000 of Curetis shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Curetis's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Curetis's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BATS-CHIXE:CUREA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 2.2%
United Kingdom of Great Britain and Northern Ireland Market Average Dividend Yield Market Cap Weighted Average of 588 Stocks 5.6%
United Kingdom of Great Britain and Northern Ireland Minimum Threshold Dividend Yield 10th Percentile 1.3%
United Kingdom of Great Britain and Northern Ireland Bottom 25% Dividend Yield 25th Percentile 2.6%
United Kingdom of Great Britain and Northern Ireland Top 25% Dividend Yield 75th Percentile 7.1%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BATS-CHIXE:CUREA Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Curetis has not reported any payouts.
  • Unable to verify if Curetis's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Curetis's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Curetis has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Curetis's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.3%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Curetis afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Curetis has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

CUREA Management

 What is the CEO of Curetis's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
  • Curetis has no CEO, or we have no data on them.
Management Team Tenure

Average tenure and age of the Curetis management team in years:

4.2
Average Tenure
50.5
Average Age
  • The tenure for the Curetis management team is about average.
Management Team

Johannes Bacher

TITLE
MD & Member of Management Board
COMPENSATION
€292K
AGE
50

Oliver Schacht

TITLE
MD & Member of Management Board
COMPENSATION
€318K
AGE
48

Achim Plum

TITLE
MD of Ares Genetics GmbH
COMPENSATION
€280K
AGE
51

Andreas Boos

TITLE
Co-Founder & CTO
COMPENSATION
€252K
AGE
59
TENURE
13.3 yrs

Bernd Bleile

TITLE
General Counsel
TENURE
4.2 yrs

Helmut Hilbert

TITLE
Head of Business Development

Andreas Posch

TITLE
Managing Director of Ares Genetics

Chris Emery

TITLE
President & CEO of Curetis USA Inc
TENURE
1.6 yrs

Faranak Atrzadeh

TITLE
Senior VP of Scientific Affairs & Marketing for Curetis USA
Board of Directors Tenure

Average tenure and age of the Curetis board of directors in years:

4
Average Tenure
57
Average Age
  • The tenure for the Curetis board of directors is about average.
Board of Directors

Werner Schäfer

TITLE
Vice-Chairman of the Supervisory Board
COMPENSATION
€83K
AGE
71
TENURE
4.4 yrs

Rudy DeKeyser

TITLE
Member of Supervisory Board
AGE
57
TENURE
5.4 yrs

Robin Patel

TITLE
Member of U.S. Scientific Advisory Board

Jean-Louis Vincent

TITLE
Member of Medical Advisory Board

Reno Frei

TITLE
Member of Medical Advisory Board

Laurent Poirel

TITLE
Member of Medical Advisory Board
TENURE
4 yrs

Melissa Miller

TITLE
Member of U.S. Scientific Advisory Board
TENURE
3 yrs

Nils Clausnitzer

TITLE
Member of Supervisory Board
COMPENSATION
€51K
AGE
49
TENURE
2.8 yrs

Debra Goff

TITLE
Member of U.S. Scientific Advisory Board

Donna Mildvan

TITLE
Member of U.S. Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • Information is not available.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
20. Jan 20 Sell Achim Plum Individual 20. Jan 20 20. Jan 20 -31,236 €0.70 €-21,865
10. Jan 20 Buy Achim Plum Individual 10. Jan 20 10. Jan 20 31,236 €0.68 €21,240
06. Jan 20 Buy Johannes Bacher Individual 06. Jan 20 06. Jan 20 31,236 €0.71 €22,178
07. Jan 20 Sell Johannes Bacher Individual 07. Jan 20 07. Jan 20 -31,236 €0.71 €-22,178
02. Jan 20 Sell Oliver Schacht Individual 02. Jan 20 02. Jan 20 -82,747 €0.70 €-57,923
24. Dec 19 Sell Johannes Bacher Individual 24. Dec 19 24. Dec 19 -15,471 €0.76 €-11,758
23. Dec 19 Sell Oliver Schacht Individual 23. Dec 19 23. Dec 19 -23,541 €0.64 €-15,066
23. Dec 19 Sell Johannes Bacher Individual 23. Dec 19 23. Dec 19 -87,000 €0.64 €-55,680
X
Management checks
We assess Curetis's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Curetis has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

CUREA News

Simply Wall St News

CUREA Company Info

Description

Curetis N.V., a commercial-stage molecular diagnostics company, provides solutions for laboratories, pharma-companies, and public hospitals in Germany and internationally. The company develops, manufactures, and commercializes molecular microbiology solutions for severe infectious diseases in hospitalized patients with a high unmet medical need that require the detection of a range of pathogens, such as bacteria and fungi, as well as toxins and genetic antimicrobial resistance markers. It provides Unyvero L4 Lysator that is used for sample pre-processing and pathogen lysis; Unyvero A50 Analyzer, which consists of mechanical, electronic, pneumatic, and optical elements; Unyvero C8 Cockpit, a device that acts as the control panel for the L4 Lysator and A50 analyzer; and Unyvero LRT, a panel for various clinically relevant bacterial targets and antibiotic resistance markers. The company also offers Unyvero Application Cartridges, which facilitates the identification of a range of disease relevant microorganisms and antibiotic resistance markers for use in syndromic infectious disease testing; and ARES AMR Database, an Ai-curated database on the genetics of antimicrobial resistances. Its cartridge-based tests are used for pneumonia, implant and tissue, blood stream, intra-abdominal, and urinary tract infections. The company has strategic partnerships with MGI Tech Co. Ltd., Qiagen N.V., Biotest AG, and Sandoz International GMBH. Curetis N.V. was founded in 2007 and is headquartered in Holzgerlingen, Germany.

Details
Name: Curetis N.V.
CUREA
Exchange: BATS-CHIXE
Founded: 2007
€14,744,407
26,282,366
Website: http://www.curetis.com
Address: Curetis N.V.
Max-Eyth-Strasse 42,
Holzgerlingen,
Baden-Württemberg, 71088,
Germany
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTAM CURE Ordinary Shares Euronext Amsterdam NL EUR 11. Nov 2015
DB CNY Ordinary Shares Deutsche Boerse AG DE EUR 11. Nov 2015
LSE 0RDD Ordinary Shares London Stock Exchange GB EUR 11. Nov 2015
BATS-CHIXE CUREA Ordinary Shares BATS 'Chi-X Europe' GB EUR 11. Nov 2015
Number of employees
Current staff
Staff numbers
110
Curetis employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/07 19:52
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2019/04/11
Last earnings filing: 2019/11/25
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.